Pfizer has issued an RPF for Artificial Intelligence/Machine Learning Research in Hemophilia.
The RFP seeks projects dedicated to Artificial Intelligence/Machine Learning, including research studies that advance artificial intelligence/machine learning methods, tools, and/or apps for application on patient data with respect to, for example, infusions, bleeds, laboratory factors, and lifestyle (a focus on emerging potential one-time treatments such as genetic medicine/gene transfer is strongly preferred); research studies that develop AI/ML methods and tools that increase the ability to predict disease risk, identify disease severity and progression due to morbidity from joint disease or recurrent bleeding, and/or improve disease management for persons with hemophilia (PWH), including optimizing treatment for patients with high-bleeding risk (e.g., severe hemophilia); research projects that develop AI/ML methods and tools that enhance patient engagement with the local hemophilia treatment center and maximize follow-up after potential one-time treatments such as gene therapy, including for patients living in remote or geographically distant areas; research projects that develop intelligent educational tools and platforms that leverage the power of AI/ML to deliver innovative educational and training programs for patients, caregivers, clinicians, healthcare providers, researchers, regulatory agencies, and policy makers (a focus on emerging potential one-time treatments such as genetic medicine/gene transfer is strongly preferred); research studies that leverage AI/ML to enhance data surveillance and increase collaboration among data partners and the ability to collect PWH-related data in real time and that link useful real world data from diverse sources (e.g., claims, EHR, registry, patient-reported outcomes, patient-level channels such as wearable devices, mobile apps, sensors); and/or the development of a recommendation system that leverages AI-NLP approach and published literature and scientific evidence to offer more personalized guidelines and algorithms with respect to monitoring adherence and outcomes.
Projects with a focus on emerging potential one-time treatments such as genetic medicine/gene transfer will receive preference. Projects requesting up to $450,000 will be considered, and Pfizer anticipates awarding a single grant.
To be eligible, the institution and principal investigator must be based in the United States.
See the Pfizer website for complete program guidelines and application instructions.